Vivian Chou, MD
Allergy & Immunology · Evanston, ILNPI 1457573420
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.2% of the total across 501 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 38 manufacturers, the largest accounting for just 19.5% — the pattern of someone who eats at a lot of different presentations.
Across 501 payments — averaging $20.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Sanofi$1K
- GSK$958
- Regeneron Healthcare Solutions, Inc.$761
- CSL Behring$584
- Pfizer$548
- plus $4K from 32 others
What the payments were for
- Consulting fees$280%
- Food & beverage$10,06397%
- Education$2663%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 93 | $2,015 |
| Sanofi | 50 | $1,154 |
| GSK | 58 | $958 |
| Regeneron Healthcare Solutions, Inc. | 31 | $761 |
| CSL Behring | 27 | $584 |
| Pfizer | 25 | $548 |
| Covis Pharma GmbH | 20 | $390 |
| Biocryst US Sales Co., LLC | 16 | $348 |
| Alk-abello, Inc | 15 | $305 |
| Genentech USA, Inc. | 14 | $289 |
| Kaleo, Inc. | 15 | $255 |
| Optinose US, Inc. | 15 | $226 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $223 |
| Hospira, Inc. | 10 | $211 |
| Pharming Healthcare, Inc. | 10 | $202 |
| Aimmune Therapeutics, Inc. | 5 | $173 |
| Amgen | 11 | $171 |
| ARS Pharmaceuticals Operations, Inc. | 7 | $156 |
| Hikma Pharmaceuticals USA | 8 | $142 |
| LEO Pharma Inc. | 6 | $133 |
| Octapharma USA, Inc. | 2 | $130 |
| Teva Pharmaceuticals USA, Inc. | 8 | $127 |
| Novartis | 7 | $117 |
| Genentech, Inc. | 2 | $94 |
| ADMA Biomanufacturing LLC | 6 | $88 |
| Phadia US Inc. | 5 | $87 |
| Shire North American Group Inc | 4 | $81 |
| Boehringer Ingelheim | 4 | $81 |
| Grifols USA, LLC | 2 | $55 |
| Bio Products Laboratory USA, Inc. | 4 | $52 |
| Kedrion Biopharma, Inc. | 3 | $47 |
| Galderma Laboratories, L.p. | 2 | $39 |
| Tersera Therapeutics LLC | 1 | $25 |
| Greer Laboratories, Inc. | 2 | $24 |
| Philips North America LLC | 1 | $21 |
| Cycle Pharmaceuticals Inc | 1 | $18 |
| Nestle Healthcare Nutrition Inc. | 1 | $14 |
| Blueprint Medicines Corporation | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PALFORZIA$114
How this compares
$10,357 in reported general payments places this provider in the 75th percentile of 161 allergy & immunology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XolairOmalizumab | 13 | $36,060 |
| Zileuton ErZileuton | 11 | $32,547 |
| Cromolyn Sodium | 16 | $17,253 |
| Epinephrine | 14 | $4,006 |
| Azelastine Hcl | 47 | $1,797 |
| Hydroxyzine Hcl | 28 | $793 |
| Fluticasone Propionate | 46 | $560 |
| Montelukast Sodium | 59 | $529 |
| Famotidine | 11 | $207 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Genentech, Inc.Xolair | $94 | $36,06013 claims |
| Cycle Pharmaceuticals IncCromolyn Sodium | $18 | $17,25316 claims |
| Hikma Pharmaceuticals USAEpinephrine | $142 | $4,00614 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 161 allergy & immunology providers in Illinois.
Other allergy & immunology in Evanston
- Amishi MurthyEvanston$9K
- Dareen SiriNormal$1.5M
- Priya BansalSaint Charles$1.3M
- Anju PetersChicago$563K
- Giselle MosnaimChicago$331K
- Patrick WinShiloh$258K
- Amanda SalihChicago$160K
- Rebecca HoffmanWilmette$160K
- Juanita MoraChicago$147K
- Sonali MajmudarAlgonquin$136K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.